--- title: "ALV-200 | PepTracker Pro" url: https://peptrackerpro.com/peptides/alv-200 description: "ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. Aliases Alveus ALV-200 +3 more Evidence Low Evidence Last Updated 2026-07-28 Reading Time 4 min ## What It Is ALV-200 is a next-generation amylin analog built around a receptor-selectivity thesis. Amylin, a pancreatic hormone co-secreted with insulin, drives satiety and slows gastric emptying and is one of obesity medicine's most clinically validated pathways beyond GLP-1. But amylin signals through several receptors: the calcitonin receptor (CTR) and the amylin receptors AMYR1, AMYR2 and AMYR3 (each formed by the calcitonin receptor paired with a receptor-activity-modifying protein, RAMP1/2/3). Most amylin analogs now in the clinic - including cagrilintide, petrelintide and older agents - are dual amylin-calcitonin receptor agonists (DACRAs) that activate CTR as well as the amylin receptors. Alveus's hypothesis, reflected in ALV-200's design, is that amylin's desirable metabolic effects (appetite suppression, weight loss and, notably, preservation of lean mass) are driven largely through AMYR3, whereas the gastrointestinal liabilities of amylin agonism - nausea, vomiting and food aversion - are driven mainly by CTR activation. By selectively agonizing AMYR3 with significant selectivity over CTR, ALV-200 aims to keep the weight-loss efficacy while improving tolerability. In Alveus's preclinical models the molecule maintained weight-loss efficacy while showing meaningful CTR selectivity, and it is engineered for once-weekly subcutaneous dosing. ALV-200 is the injectable centerpiece of Alveus's amylin franchise, which also includes oral small molecules and multifunctional formats. Alveus Therapeutics - a Philadelphia- and Copenhagen-based obesity company that launched from stealth on January 8, 2026 with a $159.8 million Series A (upsized to roughly $197 million in a February 2026 final close) - has said it plans to bring ALV-200 into first-in-human clinical studies within roughly 18 months of launch. The company's lead clinical program is ALV-100, a bifunctional GIPR-antagonist / GLP-1R-agonist fusion protein. ALV-200 reflects the broader 2026 'amylin renaissance,' in which receptor-selective and lean-mass-sparing mechanisms are being pursued as the next pillar of obesity medicine alongside GLP-1-based drugs. Also known as: Alveus ALV-200, ALV200, AMYR3-selective amylin agonist, amylin receptor 3 agonist ## Regulatory Status Investigational In IND-enabling (preclinical) development; no IND cleared and no human trials begun as of mid-2026. Alveus has stated plans to start first-in-human studies within roughly 18 months of its January 2026 launch. Not approved in any jurisdiction. Effective: 2026 View FDA Source (https://alveustx.com/science/) ## Why Researchers Study It ALV-200 tests a specific, mechanistically appealing idea: that separating amylin's benefits from its side effects is possible at the receptor level. If the beneficial metabolic effects of amylin - especially lean-mass preservation - really are AMYR3-driven while the nausea and aversion are CTR-driven, then an AMYR3-selective agonist could deliver amylin's weight-loss efficacy with markedly better gastrointestinal tolerability than the dual amylin-calcitonin receptor agonists (DACRAs) that dominate the current amylin pipeline. Researchers also study it because amylin is one of the most validated non-GLP-1 obesity pathways, because lean-mass-sparing weight loss is a central goal of next-generation obesity drugs, and because the asset is well financed and backed by a leadership team drawn from Novo Nordisk and Eli Lilly metabolic programs. ## Proposed Mechanisms - Selectively agonizes amylin receptor 3 (AMYR3) - the calcitonin receptor paired with RAMP3 - to drive satiety and weight loss - Shows significant selectivity over the calcitonin receptor (CTR), the receptor implicated in amylin-related nausea and food aversion - Aims to preserve lean mass during weight loss, an effect attributed largely to AMYR3 signaling - Engineered for once-weekly subcutaneous dosing to reduce treatment burden - Positioned as a more receptor-selective alternative to dual amylin-calcitonin receptor agonists (DACRAs) ## Evidence Snapshot Low Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Preclinical | Alveus obesity/metabolic preclinical models | ALV-200 maintained weight-loss efficacy while showing significant selectivity for AMYR3 over the calcitonin receptor (CTR); suitable for once-weekly dosing | Source: https://alveustx.com/science/ | | Company / financing | Alveus Therapeutics Series A financing | Launched Jan 8, 2026 with $159.8M Series A (upsized to ~$197M in Feb 2026); proceeds support IND filing of ALV-200 and its amylin pipeline, with first-in-human studies planned within ~18 months | Source: https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation Researching ALV-200? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=alv-200) ## Safety & Cautions - Preclinical / IND-enabling only - no human safety or efficacy data yet - The AMYR3-vs-CTR selectivity hypothesis (benefits from AMYR3, side effects from CTR) is not yet confirmed in humans - Human weight-loss magnitude, lean-mass benefit and tolerability advantage are unproven - Long-term safety and efficacy unknown - Not available outside eventual clinical trials; not FDA-approved and not a compounding-eligible peptide - Any 'ALV-200' offered by a vendor is unverified - it is a proprietary investigational candidate ## Comparisons See how ALV-200 compares to related peptides: ALV-200 vs ALV-100: https://peptrackerpro.com/compare/alv-200-vs-alv-100 ALV-200 vs Amycretin: https://peptrackerpro.com/compare/alv-200-vs-amycretin ALV-200 vs ASC39: https://peptrackerpro.com/compare/alv-200-vs-asc39 ALV-200 vs Cagrilintide: https://peptrackerpro.com/compare/alv-200-vs-cagrilintide ALV-200 vs Eloralintide: https://peptrackerpro.com/compare/alv-200-vs-eloralintide ALV-200 vs MET-233i: https://peptrackerpro.com/compare/alv-200-vs-met-233i ALV-200 vs Petrelintide: https://peptrackerpro.com/compare/alv-200-vs-petrelintide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Alveus Therapeutics - Science (ALV-200 AMYR3-selective amylin agonist) PubMed (https://alveustx.com/science/) 2. [2] Alveus Therapeutics Launches with $160 Million Series A Financing (Jan 8, 2026) PubMed (https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html) 3. [3] Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A (~$197M total) PubMed (https://www.biospace.com/press-releases/alveus-therapeutics-announces-second-and-final-closing-of-oversubscribed-series-a-bringing-total-financing-to-197-million-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases) 4. [4] Fierce Biotech - Equipped with $160M Series A, Alveus debuts into crowded obesity landscape PubMed (https://www.fiercebiotech.com/biotech/equipped-150m-series-alveus-debuts-crowded-obesity-development-landscape) ### Keep researching in the app - Log ALV-200 to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=alv-200 Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. View Details: https://peptrackerpro.com/peptides/alv-100 \+ Compare: https://peptrackerpro.com/compare?select=alv-100 Track in App: https://app.peptrackerpro.com/?add=alv-100 ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/eloralintide \+ Compare: https://peptrackerpro.com/compare?select=eloralintide Track in App: https://app.peptrackerpro.com/?add=eloralintide ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/petrelintide \+ Compare: https://peptrackerpro.com/compare?select=petrelintide Track in App: https://app.peptrackerpro.com/?add=petrelintide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "ALV-200", "description": "ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing.", "url": "https://peptrackerpro.com/peptides/alv-200", "lastReviewed": "2026-07-28", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "ALV-200", "item": "https://peptrackerpro.com/peptides/alv-200" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following amylin-based obesity drugs beyond cagrilintide and petrelintide?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-200 is a research peptide studied in preclinical models. ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing." } }, { "@type": "Question", "name": "Those interested in receptor-selective (AMYR3-selective) approaches to improving tolerability?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-200 is a research peptide studied in preclinical models. ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing." } }, { "@type": "Question", "name": "Individuals tracking lean-mass preservation and quality-of-weight-loss strategies?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-200 is a research peptide studied in preclinical models. ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing." } }, { "@type": "Question", "name": "Researchers and investors watching the 2026 'amylin renaissance' and well-financed early-stage obesity assets?", "acceptedAnswer": { "@type": "Answer", "text": "ALV-200 is a research peptide studied in preclinical models. ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing." } } ] } ] ```